439 related articles for article (PubMed ID: 32150096)
21. Clinical features of metastasis from superficial squamous cell carcinoma of the thoracic esophagus.
Miyata H; Sugimura K; Motoori M; Omori T; Yamamoto K; Yanagimoto Y; Shinno N; Yasui M; Takahashi H; Wada H; Ohue M; Yano M
Surgery; 2019 Dec; 166(6):1033-1040. PubMed ID: 31493901
[TBL] [Abstract][Full Text] [Related]
22. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature.
Liu L; Liu Y; Gong L; Zhang M; Wu W
Cancer Biol Ther; 2020 Nov; 21(11):983-989. PubMed ID: 33092443
[TBL] [Abstract][Full Text] [Related]
23. Successful conversion surgery following chemotherapy with an immune checkpoint inhibitor in an older adult patient with stage IVB esophageal squamous cell carcinoma: a case report.
Kawazoe T; Ito S; Ohgaki K; Fujinaka Y; Funakoshi H; Otake A; Wang H; Morita K; Fushimi F; Ikeda Y
Surg Case Rep; 2023 Mar; 9(1):51. PubMed ID: 36995570
[TBL] [Abstract][Full Text] [Related]
24. Case Report: Immune Checkpoint Inhibitors Successfully Controlled Asymptomatic Brain Metastasis in Esophageal Squamous Cell Carcinoma.
Xiao L; Lin C; Liu Y; Wu Y; Wang J
Front Immunol; 2022; 13():746869. PubMed ID: 35300327
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
[TBL] [Abstract][Full Text] [Related]
26. Profiles of genomic alterations in primary esophageal follicular dendritic cell sarcoma: A case report.
Ren W; Sun Q; Wu PY; Huang B; Yang J; Yan J; Liu BR
Medicine (Baltimore); 2018 Nov; 97(48):e13413. PubMed ID: 30508944
[TBL] [Abstract][Full Text] [Related]
27. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.
Tanaka T; Ueno M; Iizuka T; Hoteya S; Haruta S; Udagawa H
Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 30980070
[TBL] [Abstract][Full Text] [Related]
28. Long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma: a case report.
Ishikawa Y; Suzuki M; Yamaguchi H; Seto I; Machida M; Takagawa Y; Jingu K; Kikuchi Y; Murakami M
J Med Case Rep; 2022 Feb; 16(1):68. PubMed ID: 35152904
[TBL] [Abstract][Full Text] [Related]
29. Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
Jiang D; Song Q; Wang H; Huang J; Wang H; Hou J; Li X; Xu Y; Sujie A; Zeng H; Tan L; Hou Y
Oncotarget; 2017 Jan; 8(5):8315-8329. PubMed ID: 28039448
[TBL] [Abstract][Full Text] [Related]
30. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
31. Case Report: Durable Complete Response After Combined Immunotherapy Following Resection of Primary Tumor in a Gallbladder Cancer Patient With Distant Metastatic Lymph Nodes of Favorable Immune-Microenvironment.
Yi B; Zhao Z; Dong H; Yuan L; Wu Y; Xu Y; Jiang X; Sun C; Wu D; Xiao Y
Front Immunol; 2022; 13():820566. PubMed ID: 35242133
[TBL] [Abstract][Full Text] [Related]
32. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
33. Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer.
Yan C; Huang H; Zheng Z; Ma X; Zhao G; Zhang T; Chen X; Cao F; Wei H; Dong J; Tang P; Jiang H; Wang M; Wang P; Pang Q; Zhang W
Front Immunol; 2023; 14():1138054. PubMed ID: 37275884
[TBL] [Abstract][Full Text] [Related]
34. The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study.
Xing W; Zhao L; Zheng Y; Liu B; Liu X; Li T; Zhang Y; Ma B; Yang Y; Shang Y; Fu X; Liang G; Yuan D; Qu J; Chai X; Zhang H; Wang Z; Lin H; Liu L; Ren X; Zhang J; Gao Q
Front Immunol; 2021; 12():772450. PubMed ID: 34938292
[TBL] [Abstract][Full Text] [Related]
35. Methyl-methanesulfonate sensitivity 19 expression is associated with metastasis and chemoradiotherapy response in esophageal cancer.
Zhang JL; Wang HY; Yang Q; Lin SY; Luo GY; Zhang R; Xu GL
World J Gastroenterol; 2015 Apr; 21(14):4240-7. PubMed ID: 25892874
[TBL] [Abstract][Full Text] [Related]
36. [A case of residual metastatic lymph node lesion following definitive chemoradiotherapy for T4 esophageal cancer, successfully treated by outpatient clinic-based sequential chemotherapy with docetaxel followed by S-1].
Yoneda M; Fujiwara H; Shiozaki A; Komatsu S; Ichikawa D; Okamoto K; Murayama Y; Kuriu Y; Ikoma H; Nakanishi M; Ochiai T; Kokuba Y; Otsuji E
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2397-400. PubMed ID: 22202394
[TBL] [Abstract][Full Text] [Related]
37. Long non-coding RNA SPRY4-IT1 as a promising indicator for three field lymph-node dissection of thoracic esophageal carcinoma.
Qie P; Yin Q; Xun X; Song Y; Zhou S; Liu H; Feng J; Tian Z
J Cardiothorac Surg; 2021 Mar; 16(1):48. PubMed ID: 33757566
[TBL] [Abstract][Full Text] [Related]
38. Does cervical lymph node recurrence after oesophagectomy or definitive chemoradiotherapy for thoracic oesophageal squamous cell carcinoma benefit from salvage treatment?
Yuan X; Lv J; Dong H; Wang J
Interact Cardiovasc Thorac Surg; 2017 May; 24(5):792-795. PubMed ID: 28453803
[TBL] [Abstract][Full Text] [Related]
39. Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
Tang H; Jiang D; Zhang S; Zeng Z; Tan L; Hou Y; Wang Q; ; Wang H; Zhu J; Shen Y; Yin J; Ge D
J Thorac Cardiovasc Surg; 2021 Dec; 162(6):1632-1641. PubMed ID: 33268125
[TBL] [Abstract][Full Text] [Related]
40. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
